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Current treatment options for patients with Alzheimer’s disease (AD) are limited at pro-
viding symptomatic relief, with no effects on the underlying pathophysiology. Recently,
advances in the understanding of the AD pathogenesis highlighted the role of ABeta (Aβ)
oligomers particularly interfering with mechanisms of cortical plasticity such as long-term
potentiation (LTP) and long-term depression (LTD). These findings led to the development
of potential anti-amyloid therapies, and among them homotaurine, a glycosaminoglycan
mimetic designed to interfere with the actions of Aβ early in the cascade of amyloidogenic
events, and by its γ-aminobutyric acid type (GABA) A receptor affinity. Recently, we showed
that AD patients have impaired LTP-like cortical plasticity, as measured by standard theta
burst stimulation protocols applied over the primary motor cortex (M1). Furthermore, AD
patients have a weakened short latency afferent inhibition (SLAI), a neurophysiological mea-
sure of central cholinergic transmission, which changes reflect the cholinergic dysfunction
occurring in the pathology. Here, we aimed at investigating whether homotaurine admin-
istration could modulate in vivo measured mechanisms of synaptic plasticity, namely LTP
and LTD, and also SLAI in a group of mild cognitive impaired patients. We observed that
homotaurine administration did not induce relevant changes of both LTP and LTD record-
ings, while induced changes of SLAI in our group of patients.We suggest that homotaurine
effects are dependent on changes of cortical GABA transmission suggesting a potential role
for this compound in ameliorating the cholinergic transmission by modulating the inhibitory
cortical activity.
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INTRODUCTION
Mild cognitive impairment (MCI) is a cognitive status difficult
to define. It represents the gray area set between the normal
and pathologic cognition. Its definition and description of clinic-
pathological features depends on the different methods used to
assess MCI (Petersen et al., 2014). Given its dynamic evolution, it is
in general considered a pre-clinical condition during which patho-
logical changes may occur long before cognitive decline appear.
MCI could evolve in cognitive decline of Alzheimer’s type, fronto-
temporal dementia, Parkinson’s disease, etc. (de Mendonça et al.,
2004, 2005; Aarsland et al., 2011), and in this view, features like
biomarkers, neuropsychological assessment, and radiological signs
could be helpful to define its nature. MCI of Alzheimer’s demen-
tia type is suggested to recognize the same pathological back-
ground, although factors responsible for its evolution toward AD
remain unknown (Grundman et al., 2004). AD is an age-related
neurodegenerative disorder responsible for progressive cognitive
decline and dementia. It is the most diffuse form of demen-
tia worldwide. Pathologic hallmark of AD is extracellular senile
plaques and intracellular neurofibrillary tangles. The pathogene-
sis of AD is debated. Current and leading pathogenic hypothesis
is the so-called amyloid hypothesis (Hardy and Selkoe, 2002).
The amyloid precursor protein (APP) is a transmembrane protein
with unknown function. Changes in APP proteolytic processing
are considered central in AD pathogenesis, where an imbalance
between amyloidogenic (beta and gamma-secretase mediated) and
non-amyloidogenic (alpha-secretase mediated) pathways, could
be responsible for the overproduction of insoluble amyloid pep-
tides. The progressive accumulation of these peptides, associated
with a reduced clearance, would promote aggregation of Aβ pep-
tides in oligomers and fibrils, species with a powerful toxic effect
on neurons responsible for dramatic changes of synaptic plasticity
machinery with impaired long-term potentiation (LTP) and pro-
longed long-term depression (LTD), spine shrinkage and loss, and
neuronal degeneration (Shankar et al., 2008; Palop and Mucke,
2010). These changes are supposed to start long before cognitive
decline appear, therefore, low Aβ levels could be easily detected in
MCI patients. Since that, MCI is often considered a state during
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which therapies to delay or modify pathologic cascade of AD could
be taken (Simon et al., 2012; Ghosh et al., 2013). Homotaurine
or Tramiprosate, is a small aminosulfonate compound naturally
found in seaweeds. It is a compound with features typical of gly-
cosaminoglycanes (GAGs) (Wright, 2006). These are compounds
able to induce and enhance Aβ aggregation, fibrillogenesis with
neurotoxic effect on neurons. Homotaurine on the contrary has
been shown to be able to counteract Aβfibrillogenesis reducing the
toxic effects on neurons. Indeed, in experimental models homo-
taurine administration induced inhibition of Aβ fibrils formation,
reduction of the brain pathologic burden, and formation of phys-
iological LTP (Gervais et al., 2007). Moreover, early studies made
in humans showed that homotaurine induces a dose-dependent
reduction of Aβ1-42 cerebrospinal levels in AD patients (Aisen
et al., 2007), with reduction of brain atrophy (Gauthier et al.,
2009) and positive cognitive measurable effects (Saumier et al.,
2009). These features suggest potential neuroprotective effects of
homotaurine that could be useful in therapeutic strategies in early
phases of AD (Caltagirone et al., 2012). Besides the anti-amyloid
action, homotaurine has direct effects also on neuronal activity
as a modulator of excitatory neurotransmission, due to its bind-
ing affinity for GABAA receptors (GABAARs). This modulatory
action strengthens the potential neuroprotection mechanisms of
homotaurine. Such potential neuroprotective effects could be use-
ful for MCI patients to delay progression to cognitive decline,
although few literature addressed such target.
Here, we aimed to verify whether homotaurine administration
could induce changes of cortical activity in vivo, measurable with
electrophysiological tools validated for humans. The aim of this
work was to study the effects of homotaurine on motor cortical
excitability using standard paired-pulse protocols assessing short
intracortical inhibition (SICI) and intracortical facilitation (ICF)
and on cholinergic transmission using short latency afferent inhi-
bition (SLAI) paradigm, in a group of MCI patients. Each patient
was evaluated for plasticity induction of LTP/LTD-like effects using
respectively intermittent TBS (iTBS) or continuous TBS (cTBS)
protocols of repetitive transcranial stimulation as well. Parallel
neuropsychological assessment was performed at the baseline and
following 4 weeks treatment.
MATERIALS AND METHODS
SUBJECTS
We examined 10 patients with a diagnosis of amnestic MCI
according to the Petersen criteria. The mean (±SD) age of the
patients was 61.9 (±1.9) years (for patients characteristics see
Table 1). All patients underwent a complete clinical investiga-
tion, including medical history, neurological examination, mini
mental state examination (MMSE), a complete blood screening
(including routine exams, thyroid hormones, level of B12), neu-
ropsychological examination (Pierantozzi et al., 2004), a complete
neuropsychiatric evaluation, and neuroimaging consisting of mag-
netic resonance imaging (1.5 T MRI). Exclusion criteria were the
following: (1) patients with isolated deficits and/or unmodified
MMSE (≥25/30) on revisit (6, 12, and 18 months follow-up),
patients with clinically manifest acute stroke in the last 6 months
showing an Hachinsky scale >4, and a radiological evidence of
sub-cortical lesions. None of patients revealed pyramidal and/or
Table 1 | Demographic characteristic of the MCI patients.
Gender Education Age
1 F 5 72
2 F 13 72
3 M 2 59
4 F 5 70
5 F 3 74
6 M 3 73
7 M 8 70
8 M 5 73
9 M 13 64
10 M 8 63
extrapyramidal signs at the neurological examination. At the time
of enrollment, in the 30 days before participating in this study,
none of the patients had been treated with drugs that might
have modulated cerebral cortex excitability such as antidepres-
sants, or any other neuroactive drugs (i.e., benzodiazepines, anti-
epileptic drugs, or neuroleptics), and they had not been treated
with cholinesterase inhibitors. The study was performed accord-
ing to the Declaration of Helsinki and approved by the ethics
committee of the Tor Vergata University in Rome. The Local Ethic
Committee approved the study procedures.
Drug administration
Homotaurine 100 mg was administered for a period of 4 weeks in
order to maximize the pharmacological effect of the drug. All par-
ticipants were tested on Monday before and after the 4 weeks of
homotaurine administration. To guarantee the reliability of TMS
results, physicians involved in recordings were completely blinded
to the kind of experiments used in this protocol. None of the
patients receiving homotaurine complained for side effects.
TMS procedure
Single and paired TMS of the motor cortex of both hemispheres
were performed with a 9 cm figure-of-eight coil connected with
one or two Magstim 200 stimulators (The Magstim Company,
Whitland, UK) via one Bistim module. The magnetic stimuli had a
nearly monophasic pulse configuration, with a rise time of 100µs,
decaying back to zero over 0.8 ms. For paired-pulse protocols, the
output of each of the two Magstim 200 stimulators was connected
to the TMS coil using a cable. The coil was placed at the optimal
position for eliciting motor-evoked potentials (MEPs) from the
contralateral first dorsal interosseous (FDI) muscle. The optimal
position was marked on the scalp with a felt pen to ensure the iden-
tical placement of the coil throughout the experiment. The handle
of the coil pointed backward and was perpendicular to the pre-
sumed direction of the central sulcus, about 45° to the midsagittal
line. The direction of the induced current was from posterior to
anterior, and was optimal to activate the motor cortex transsy-
naptically (Werhahn et al., 1994). The resting motor threshold
(RMT) was defined as the lowest intensity that produced MEPs of
>50µV in at least 5 of 10 trials with the muscles relaxed (Rossini
et al., 1994). The active motor threshold (AMT) was defined as
the lowest intensity that produced MEPs of >200µV in at least
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5 of 10 trials when the subject made a 10% of maximum con-
traction using visual feedback (Rothwell, 1997). Determination of
RMT and AMT was done in step width of 1% of MSO. SICI and
ICF were tested using paired TMS with a subthreshold condition-
ing stimulus (CS) preceding a suprathreshold test stimulus (TS)
(Kujirai et al., 1993; Rothwell, 1997). Subthreshold CS stimulus
was set at 80% AMT while the intensity of TS was adjusted to
evoke a MEP of 1 mV peak-to-peak in the relaxed left FDI. Inter-
stimulus intervals (ISIs) of 1, 2, 3, 5, 7, 10, and 15 ms were utilized
to test SICI and ICF.
Short latency afferent inhibition protocol
Short latency afferent inhibition was studied using the technique
that has been recently described (Sailer et al., 2003; Lang et al.,
2008). CS were single pulses (200µs) of electrical stimulation
applied through bipolar electrodes to the right median nerve at
the wrist (cathode proximal). The intensity of the CS was set at
just over motor threshold for evoking a visible twitch of the thenar
muscles. The intensity of the test cortical magnetic stimulus was
adjusted to evoke a muscle response in relaxed right FDI with an
amplitude of 1 mV peak-to-peak. The CS to the peripheral nerve
preceded the magnetic TS by different ISIs. ISIs were determined
relative to the latency of the N20 component of the somatosen-
sory evoked potential induced by stimulation of the right median
nerve. The active electrode for recording the N20 potential was
attached 3 cm posterior to C3 (10–20 system) and the reference
was 3 cm posterior to C4. Five hundred responses were averaged
to identify the latency of the N20 peak. ISIs from the latency of the
N20 minus 4 ms to the latency of the N20 plus 8 ms were investi-
gated in steps of 4 ms. Ten stimuli were delivered at each ISI. The
subject was given audiovisual feedback at high gain to assist in
maintaining complete relaxation. The inter-trial interval was set
at 5 s (±10%), for a total duration of 5 min. Measurements were
made on each individual trial. The mean peak-to-peak amplitude
of the conditioned MEP at each ISI was expressed as a percentage
of the mean peak-to-peak amplitude size of the unconditioned
test pulse in that block.
Theta burst stimulation protocol
Motor-evoked potentials were recorded from the right FDI
muscles using 9 mm diameter, Ag–AgCl surface cup electrodes.
Responses were amplified with a Digitimer D360 amplifier (Dig-
itimer Ltd., UK) through filters set at 20 and 2 kHz, then recorded
by computer using SIGNAL software, at a sampling rate of 5 kHz
per channel (Cambridge Electronic Devices, UK). A monopha-
sic Magstim 200 device (Magstim Co., UK) was used to define
the motor hot-spot and to assess MEP size. The motor hot-spot
was defined as the location where TMS consistently produced the
largest MEP size at 120% of RMT in the target muscle (Rossini
et al., 1994). A second coil was connected to a biphasic Super
Rapid Magstim stimulator (Magstim Co., UK) to deliver rTMS. In
the theta burst stimulation (TBS) protocols bursts were repeated
at 5 Hz (i.e., every 200 ms), while each burst consisted of three
stimuli repeating at 50 Hz. For iTBS, a 2 s train of TBS at 80%
AMT was repeated 20 times, every 10 s for a total of 190 s (600
pulses) (Huang et al., 2005). Twenty MEPs were collected and
averaged at baseline. The intensity of the test pulse was adjusted
throughout the experiment so that it evoked a MEP of about 1 mV
peak-to-peak amplitude in each individual. Then, over the same
hot-spot, 20 MEPs were recorded at 1–5, 6–10, 11–15, 16–20, and
21–25 min after rTMS, and averaged. SLAI was investigated using
the technique that has been recently described (Sailer et al., 2003;
Lang et al., 2008), where the CS is a single pulse (200µs) of elec-
trical stimulation applied through bipolar electrodes to the right
median nerve at the wrist (cathode proximal). The intensity of the
CS was set at just over motor threshold for evoking a visible twitch
of the thenar muscles. The intensity of the cortical magnetic TS
was adjusted to evoke a muscle response in the relaxed right FDI
with an amplitude of about 1 mV peak-to-peak. The CS to the
peripheral nerve preceded the cortical magnetic TS by different
ISIs, which ranged from −4 to +8 ms from the N20 component,
in steps of 4 ms (Martorana et al., 2013). Ten stimuli were delivered
at each ISI. Subjects were provided with audiovisual feedback at
high gain, in order to assist them in maintaining complete relax-
ation. The inter-trial interval was set at 5 s (±10%), for a total
duration of 5 min. Measurements were made on each individual
trial. The mean peak-to-peak amplitude of the conditioned MEP
at each ISI was expressed as a percentage of the mean peak-to-peak
amplitude of the unconditioned test pulse in that block.
Cognitive assessment
All the patients underwent a neuropsychological examination
including a general cognitive index (Mini Mental Examination
State (Martorana et al., 2013) and the following neuropsycholog-
ical tests for the specific cognitive domains: (1) 15 Rey’s Word
List (Immediate and 15-min Delayed recall) to investigate verbal
episodic long-term memory (Magni et al., 1996); (2) forward and
backward Digit span (Carlesimo et al., 1996) and the forward and
backward Corsi Block Tapping task (Orsini et al., 1987) to inves-
tigate short-term memory and working memory; Frontal Assess-
ment Battery (FAB) to investigate executive functions (Appollonio
et al., 2005). Parallel versions were used when available.
DATA ANALYSIS
Data were analyzed using SPSS for Windows version 11.0; we mea-
sured the percentage of change of peak-to-peak amplitudes of
the mean MEPs at baseline for each subject in each condition.
At baseline two-way repeated measure ANOVAs were performed
for each protocol (cTBS and iTBS) with TIME (1–5, 6–10, 11–
15,16–20, and 21–25 min after TBS) as within subjects factor. To
test the effects of the drugs, different repeated measure ANOVAs
were performed for each protocol (cTBS and iTBS) with SESSION
(baseline vs. end of treatment) and TIME (1–5,6–10,11–15,16–20,
and 21–25 min after TBS) as within subjects factors.
For SLAI, the electrophysiological parameters of AD patients
were analyzed by means of repeated measures ANOVA with ISI
16, 20, 24, and 28 ms(−4, 0,+4, and+8 ms plus the latency of the
N20) and TIME (before vs. after homotaurine administration) as
within subjects factors.
For SICI and ICF, we performed a repeated measures analysis
ANOVA with ISI (1, 2, 3, 5, 7, 10, and 15 ms) and TIME (before vs.
after homotaurine administration) as within subjects factors.
The Greenhouse–Geisser correction was used for non-spherical
data. When a significant main effect was reached, paired t -tests
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with Bonferroni correction (p< 0.05) were employed to charac-
terize the different effects for the specific ISIs. Mauchley’s test
examined for sphericity. For all statistical analyses, a p value<0.05
was considered to be significant.
RESULTS
The entire procedure was well tolerated in all subjects. The mean
(standard deviation) AMT (calculated as a percentage of maximal
stimulator output, MSO) for TMS was PLC: 35.2%.
Repeated ANOVA analysis performed on SLAI measurements
revealed a significant ISI [F(3,27)= 12.68, p= 0.00002] main fac-
tor; the interaction ISI×TIME was significant [F(3, 27)= 3.65,
p= 0.024]. Post hoc analyses showed that homotaurine increased
SAI at ISIs 20 ms (p= 0.047) and 24 ms (p= 0.031) (Figure 1A).
The ANOVA analysis performed on SICI and ICF measure-
ments revealed a significant ISI [F(6, 30)= 5.88, p= 0.00038]
main factor; the interaction ISI×TIME was not significant
[F(6, 30)= 0.51, p= 0.79] (Figure 1B). Homotaurine did not
induce any effect on the iTBS (Figure 1C) protocol as shown
by the ANOVA [SESSION main factor: F(1, 9)= 1.08, p= 0.32;
TIME main factor: F(4, 36)= 1.63, p= 0.19; interaction SES-
SION×TIME:F(8, 1)= 0.70;p= 0.78]. Finally, Homotaurine did
not induce any effect on the cTBS protocol as shown by the ANOVA
[SESSION main factor: F(1, 9)= 0.07, p= 0.78; TIME main
factor: F(4, 36)= 0.17, p= 0.95; interaction SESSION×TIME:
F(4,36)= 0.40; p= 0.81] (Figure 1D).
Neuropsychological scores obtained at baseline and with those
obtained after 4 weeks of treatment were compared (see also
Table 2). MMSE, RAVLT, Digit span, Corsi span, and FAB scores
did not vary after 4 weeks of treatment with homotaurine.
DISCUSSION
The anti-amyloid properties associated to the GABA profile, make
homotaurine a new potential drug for treatment of AD (Cal-
tagirone et al., 2012). Since most of the pathological changes
observed in AD have been shown to start long before cognitive
decline appears (Mattsson et al., 2009; Lim et al., 2014), an appro-
priate treatment strategy would indicate homotaurine for patients
with MCI, a condition that potentially reverse to AD. Homotaurine
has been introduced in pharmacotherapy only recently and litera-
ture on MCI is scarce. Here, we tested the effects of homotaurine
on excitability of the motor cortex and on synaptic plasticity mech-
anisms by means of neurophysiological protocols on individuals
with MCI. Following 4 weeks of treatment, homotaurine induced
changes of SLAI cortical inhibitory circuit, without changes of
SICI, but was unable to induce changes of the LTP/LTD mecha-
nisms. It is questionable whether the effects we measured are the
consequence of anti-amyloid activity or of the high affinity bind-
ing of homotaurine for GABAARs. We suppose that the latter is
the most likely effect. Cortical neurones are excitatory glutamater-
gic neurones that project downstream to spinal cord and in part to
basal ganglia system. Pyramidal neurons excitability is modulated
by the inhibitory activity of the intracortical GABA interneurons.
It is supposed that GABA released from interneurons would act
on GABAAR expressed on pyramidal neurones. Such inhibitory
effect could be reliably measured by paired TMS protocol. The
measure obtained called SICI is the result of the GABA intracor-
tical interneurons activation. SLAI instead is a neurophysiological
tool that in general is considered a measure of inhibitory inter-
actions between afferent input and motor output. It is supposed
that cholinergic system modulates these inhibitory interactions,
FIGURE 1 | Effects of 4weeks of homotaurine-based treatment on neurophysiological parameters. Homotaurine increased SAI efficiency (A). No effect
was observed for SICI and ICF (B), iTBS (C), and cTBS (D) protocols.
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Table 2 | Neuropsychological assessment of MCI patients.
Pre Post
MMSE FAB Rey
R. I.
Rey
R. D.
VS
FW
SS
FW
VS
BW
SS
BW
MMSE FAB Rey R. I. Rey
R. D.
VS
FW
SS
FW
VS
BW
SS
BW
1 26.3 13.5 29.74 5.66 5.15 4.58 3 4 26.3 14.5 27.74 6.66 4.15 4.58 4 3
2 25.7 14.3 23.93 0 4.44 4.18 4 4 25.7 16.3 29.93 3.47 5.44 4.18 4 4
3 25 16.3 36.94 6.8 4.71 4.34 4 2 25 14.3 40.94 8.8 4.71 4.34 2 3
4 25.7 14.3 28.95 6.39 5.17 3.55 3 3 25.3 12.3 39.95 9.39 6.17 3.55 3 3
5 26.7 14 25.32 4.37 4.39 5.72 2 4 25.3 14 25.32 4.37 4.39 5.72 2 4
6 26.7 12 26.91 4.23 4.4 4.52 3 5 26.7 14 29.91 0 4.4 5.52 4 5
7 29 8.3 21.34 0 3.55 3.64 3 3 29 8.3 21.34 0 3.55 3.64 3 3
8 28.5 13.2 27.59 3.9 4.53 4.36 3.14 3 29 13.2 27.59 3.9 4.5 4.3 3.1 4
9 28 7.5 21.34 0 5.16 4.56 5 3 28.3 7.5 21.34 0 5.16 4.56 5 3
10 27 12.6 26.89 3.4 4.61 4.38 3.34 3 27 12.6 26.8 3.4 4.6 4.3 3.3 3
For each administered test appropriate adjustments for sex, age, and education were applied according to the Italian normative data. Neuropsychological measure-
ments did not differ after 4weeks of treatment with homotaurine. MMSE, mini mental state examination; FAB, frontal assessment battery; REY R. I., Rey recall
immediate; Rey R. D., Rey recall delayed; VS FW, verbal span forward; SS FW, spatial span forward; VS BW, verbal span backward; SS BW, spatial span backward.
and that GABA-PV interneurons drive these interactions. SLAI
measures are altered in patients suffering from cognitive decline
of Alzheimer’s type (Di Lazzaro et al., 2002), and are reported to be
normal in MCI patients (Sakuma et al., 2007). SICI and SLAI are
two different forms of cortical inhibition (Ziemann et al., 1996; Di
Lazzaro et al., 1998; Tokimura et al., 2000). Both can be segregated
by electrophysiological and pharmacological profile. Pharmaco-
logical profiling distinguishes SLAI from SICI because only SLAI
but not SICI decreases with blockade of cholinergic M1 receptors
(Di Lazzaro et al., 2000). In addition, the classical benzodiazepine
lorazepam increases SICI but decreases SLAI (Di Lazzaro et al.,
2005a,b), and zolpidem, a positive modulator at the GABAAR with
high affinity to theα1 subtype of the GABAAR, does not affect SICI
but decreases SAI (Di Lazzaro et al., 2007). These data led to sup-
pose the existence of at least partially distinct inhibitory neuronal
circuits in the central nervous system. Recent electrophysiological
findings strongly support the idea that SICI and SLAI are medi-
ated through two distinct and reciprocally connected subtypes
of GABA inhibitory interneurons with convergent projections
onto the corticospinal neurons. Moreover, since SICI interneurons
dominate on SLAI interneurons, it is suggested that SICI interneu-
rons target the corticospinal neurons closer to their axon initial
segment than the SLAI interneuron (Alle et al., 2009). Our findings
are in line with these data, and support the idea that homotaurine
elicits SLAI without interfering with SICI, thus acts on one of the
distinct inhibitory circuits. In addition, it may be suggested a direct
effect of homotaurine on cortical cholinergic terminals from basal
forebrain neurons. The hypothesis seems unlikely since cholin-
ergic neurons do not express receptors for GABA (Henderson,
1995; Mufson et al., 2003). We therefore suggest that homotau-
rine act directly on cortical interneurones through its high affinity
binding to GABAARs, mimicking the effects of cholinergic trans-
mission. Although homotaurine induced changes of intracortical
inhibitory circuits, changes of LTP/LTD mechanisms were not
observed. Earlier experiments performed in lab animals or in
humans showed the potential of homotaurine to maintain LTP
(Gervais et al., 2007), and also to interfere with Aβ fibril formation,
two action that has been connected obeying to the amyloid cascade
events (Aisen et al., 2007, 2011; Gauthier et al., 2009). Moreover,
homotaurine produced measurable effects on cognition as well
(Saumier et al., 2009). In our study, neuropsychological assessment
showed no significant difference with respect to baseline. Reason of
such discrepancies could be easily ascribed to the fact that available
literature focused on AD patients, different doses of homotaurine
has been used and for more prolonged time. All conditions that was
supposed to interfere potentially with amyloid deposition. Here,
we focused on MCI patients, for a relatively reduced time, condi-
tions that highlighted the GABA-mediated effects of homotaurine
rather than the potential anti-amyloid effects. Furthermore, it is
noteworthy that we did not perform CSF biomarker analysis of our
sample of patients. Recent studies on MCI patients, showed that in
some cases pathologic Aβ 1–42 levels could be detected even 10–
15 years before cognitive decline appears (Bondi et al., 2014). Thus,
it may be supposed that our patients have a normal biomarker
profile, and therefore the homotaurine efficacy resulted difficult
to evaluate in both cognitive and electrophysiological tools. Par-
ticularly, the lack of effect on neuropsychological evaluation could
be due to the fact that anti-amyloid activity contributes to stabilize
a degenerative process while is not able to ameliorate measurable
cognitive functions. On the other hand, it is conceivable to suppose
that the traditional neuropsychological evaluation shows limits
both in evaluating the cognitive impairment of MCI subjects, as
recently discussed (Hansson et al., 2006) and their relief. However,
more studies with larger sample MCI patients, using revised and
adequate neuropsychological tools, possibly with different CSF
biomarkers pattern (normal vs. pathologic Aβ 1–42 levels) could
be of interest. Similarly, evaluation of homotaurine administration
on SLAI in AD patients could help to better define the pharmaco-
logical homotaurine profile and also its indication in treatment of
cognitive decline symptoms. In conclusion, this work represents an
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early pre-clinical study, and describes to our knowledge for the first
time, the homotaurine effects on human inhibitory cortical activ-
ity, mimicking the effects observed for the cholinomimetic drugs
(Di Lazzaro et al., 2002), useful to enhance cognition. Further clin-
ical studies properly designed are needed however to fully evaluate
homotaurine potential effects in treatment of MCI patients.
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